Tuberculosis
- PMID: 30904262
- DOI: 10.1016/S0140-6736(19)30308-3
Tuberculosis
Abstract
Tuberculosis remains the leading cause of death from an infectious disease among adults worldwide, with more than 10 million people becoming newly sick from tuberculosis each year. Advances in diagnosis, including the use of rapid molecular testing and whole-genome sequencing in both sputum and non-sputum samples, could change this situation. Although little has changed in the treatment of drug-susceptible tuberculosis, data on increased efficacy with new and repurposed drugs have led WHO to recommend all-oral therapy for drug-resistant tuberculosis for the first time ever in 2018. Studies have shown that shorter latent tuberculosis prevention regimens containing rifampicin or rifapentine are as effective as longer, isoniazid-based regimens, and there is a promising vaccine candidate to prevent the progression of infection to the disease. But new tools alone are not sufficient. Advances must be made in providing high-quality, people-centred care for tuberculosis. Renewed political will, coupled with improved access to quality care, could relegate the morbidity, mortality, and stigma long associated with tuberculosis, to the past.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.J Assoc Physicians India. 2006 Mar;54:219-34. J Assoc Physicians India. 2006. PMID: 16800350
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.Paediatr Drugs. 2005;7(4):219-34. doi: 10.2165/00148581-200507040-00002. Paediatr Drugs. 2005. PMID: 16117559 Review.
-
Tuberculosis: a new vision for the 21st century.Kekkaku. 2009 Nov;84(11):721-6. Kekkaku. 2009. PMID: 19999594
-
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.Evid Based Child Health. 2014 Mar;9(1):169-294. doi: 10.1002/ebch.1962. Evid Based Child Health. 2014. PMID: 25404581
Cited by
-
Spatial and temporal analysis and forecasting of TB reported incidence in western China.BMC Public Health. 2024 Sep 13;24(1):2504. doi: 10.1186/s12889-024-19994-6. BMC Public Health. 2024. PMID: 39272092 Free PMC article.
-
Rapid and Highly Sensitive Detection of Mycobacterium tuberculosis Utilizing the Recombinase Aided Amplification-Based CRISPR-Cas13a System.Microorganisms. 2024 Jul 23;12(8):1507. doi: 10.3390/microorganisms12081507. Microorganisms. 2024. PMID: 39203350 Free PMC article.
-
Single-cell transcriptome sequencing reveals altered peripheral blood immune cells in patients with severe tuberculosis.Eur J Med Res. 2024 Aug 29;29(1):434. doi: 10.1186/s40001-024-01991-5. Eur J Med Res. 2024. PMID: 39198909 Free PMC article.
-
Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis.J Clin Tuberc Other Mycobact Dis. 2024 Jul 27;37:100470. doi: 10.1016/j.jctube.2024.100470. eCollection 2024 Dec. J Clin Tuberc Other Mycobact Dis. 2024. PMID: 39188351 Free PMC article. Review.
-
Expanding the chemical space of ester of quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives as potential antitubercular agents.RSC Med Chem. 2024 Jul 17;15(8):2785-2791. doi: 10.1039/d4md00221k. eCollection 2024 Aug 14. RSC Med Chem. 2024. PMID: 39149106
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous